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Abstract
Background: β-Alanine (βA) has been shown to improve performance during cycling. This study was the first to 
examine the effects of βA supplementation on the onset of blood lactate accumulation (OBLA) during incremental 
treadmill running.
Methods: Seventeen recreationally-active men (mean ± SE 24.9 ± 4.7 yrs, 180.6 ± 8.9 cm, 79.25 ± 9.0 kg) participated in 
this randomized, double-blind, placebo-controlled pre/post test 2-treatment experimental design. Subjects 
participated in two incremental treadmill tests before and after 28 days of supplementation with either βA (6.0 g·d-
1)(βA, n = 8) or an equivalent dose of Maltodextrin as the Placebo (PL, n = 9). Heart rate, percent heart rate maximum 
(%HRmax), %VO2max@OBLA (4.0 mmol.L-1 blood lactate concentration) and VO2max (L.min-1) were determined for each 
treadmill test. Friedman test was used to determine within group differences; and Mann-Whitney was used to 
determine between group differences for pre and post values (p < 0.05).
Results: The βA group experienced a significant rightward shift in HR@OBLA beats.min-1 (p < 0.01) pre/post (161.6 ± 
19.2 to 173.6 ± 9.9) but remained unchanged in the PL group (166.8 ± 15.8 to 169.6 ± 16.1). The %HRmax@OBLA 
increased (p < 0.05) pre/post in the βA group (83.0% ± 9.7 to 88.6% ± 3.7) versus no change in the PL group (86.3 ± % 
4.8 to 87.9% ± 7.2). The %VO2max@OBLA increased (p < 0.05) in the βA group pre/post (69.1 ± 11.0 to 75.6 ± 10.7) but 
remained unchanged in the PL group (73.3 ± 7.3 to 74.3 ± 7.3). VO2max (L.min-1) decreased (p < 0.01) in the βA group 
pre/post (4.57 ± 0.8 to 4.31 ± 0.8) versus no change in the PL group (4.04 ± 0.7 to 4.18 ± 0.8). Body mass kg increased (p 
< 0.05) in the βA group pre/post (77.9 ± 9.0 to 78.3 ± 9.3) while the PL group was unchanged (80.6 ± 9.1 to 80.4 ± 9.0).
Conclusions: βA supplementation for 28 days enhanced sub-maximal endurance performance by delaying OBLA. 
However, βA supplemented individuals had a reduced aerobic capacity as evidenced by the decrease in VO2max values 
post supplementation.
Background
Running is a popular form of exercise in the United States
and for many it is considered a competitive sport. While
performance goals can range from simply finishing a race
to competition in an Olympic event, it is likely that many
participants seeking to improve performance use various
nutritional supplements.
One such supplement that has recently received inter-
est in improving exercise performance is Beta-Alanine
(βA) [1-10]. βA is a non-proteinogenic amino acid that is
synthesized in the liver as the final metabolite of uracil
and thymine degradation. While produced endogenously,
the primary source of βA in humans comes from their
diet. Meat is the primary source of dietary βA, with high-
est concentrations found in chicken and turkey [11]. The
performance enhancing potential of βA supplementation
lies in its effect on increasing muscle carnosine levels
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[4,7,8,12] due to its role as the limiting factor in the mus-
cle carnosine synthesis [12-14].
Carnosine (β-alanyl-L-histidine) is a dipeptide found in
muscle tissue that acts as an intramuscular buffer of [H+]
[4,7,8,12]. During high intensity exercise, a greater reli-
ance on the glycolysis and phosphagen systems to supply
ATP to working muscles results in an accumulation of
[H+] which leads to exercise-induced metabolic acidosis
[15]. A decline in pH has been implicated as a cause of
muscle fatigue and decreased muscle contractile function
[16]. Attenuating exercise induced acidosis is purported
to result in performance improvements in activities
requiring prolonged bouts of high intensity work. This is
supported by findings that muscle carnosine concentra-
tions are higher in sprinters [17], bodybuilders [18], and
team sport athletes regularly participating in high inten-
sity intermittent exercise [19,20] than in their sedentary
counterparts.
Previous studies investigating the effect of βA on per-
formance measures have shown improvements in total
work done (TWD) [4,10], time to exhaustion (TTE)
[1,4,10], physical working capacity at fatigue threshold
(PWCFT) [1,3], power output at lactate threshold (LT)
[5], attenuated fatigue during repeated bouts of resistance
training [7], and final 30 second sprint performance dur-
ing a 2 hour time trial [9]. Research has however been
conducted using primarily cycle ergometry [1-5,9,10], so
it remains to be determined if βA supplementation would
have an ergogenic effect during running performance.
Therefore, we hypothesized that βA supplementation
would delay OBLA. Therefore, the purpose of this study
was to determine the effects of 4 weeks of βA supplemen-
tation on HR@OBLA, %HRmax@OBLA,




Seventeen men who were recreationally active and run-
ning at least 3 times per week and had not taken any
sports supplements for at least 6 weeks volunteered to
participate in this study (Table 1). Subjects provided
signed consent to participate and all study procedures
were approved by the Northern Illinois University Insti-
tutional review board prior to enrollment in the study.
Experimental Design
This study used a double-blind-placebo-controlled pre/
post test 2-treatment experimental design. On days 1 and
29, subjects reported to the exercise lab for anthropomet-
ric collection and to perform an incremental treadmill
running protocol. During the 28 day study, subjects were
randomly assigned to consume a supplement containing
either βA (6.0 g·d-1) or Placebo (PL) Maltodextrin (6.0 g·d-
1). Pre- and post-supplementation testing took place at
the same time of day for each subject and on the same
equipment. Subjects were asked to fast for 2 hrs prior to
each test. Subjects were asked to abstain from taking any
other dietary supplements and to maintain their regular
diet and exercise patterns for the duration of the study.
Subjects were also required to abstain from caffeine or
vigorous exercise for 24 hrs before exercise testing.
Anthropometric data were recorded in light exercise
clothing and bare feet using a wall mounted stadiometer
and calibrated digital scale (Tanita Body Composition
Analyzer TBF-300A, Tanita Corp, Arlington Heights, IL).
Subjects were connected to an automated metabolic
measurement system (Parvomedics TrueMax 2400, Con-
sentius Technologies, Sandy, UT) via mouthpiece and
headset and fitted with a telemetric heart rate monitor
(Polar F6, Finland) in seated position for resting variables
prior to testing.
Participants performed 3 minutes of walking on the
treadmill at 6.4 km.hr-1 (4.0 mph) to acclimate to the
apparatus. The treadmill was then set at a fixed 9.6 km.hr-
1 (6.0 mph) for the duration of the test. Every 3 minutes,
the treadmill incline was increased by 2% grade. After
stage 5, any remaining stages ensued at 3% grade increase
(stages: 0%, 2%, 4%, 6%, 8%, 11%, 14%, 17%). The test con-
tinued until the participant reached volitional exhaustion.
Oxygen uptake was obtained every 30 seconds (s)
throughout the test. VO2max was recorded as the highest
30 s average recorded prior to volitional exhaustion. Cri-
teria for VO2max was attainment of at least two or more of
the following: reaching a plateau in VO2 (< 2.1 ml.kg-
1.min-1 increase) the final two stages of the test, achieving
Table 1: Physical Characteristics of Subjects.
Variable βA (n = 8) PL (n = 9)
Age (yr) 24.9 ± 5.1 24.9 ± 4.3
Height (cm) 181.4 ± 9.9 179.8 ± 7.9
Body Mass (kg) 77.9 ± 9.0 80.6 ± 9.1
BMI 23.7 ± 2.3 24.9 ± 1.8
Values are means ± SEJordan et al. Journal of the International Society of Sports Nutrition 2010, 7:20
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a respiratory exchange ratio (RER ≥ 1.10) and/or reaching
a HR within 5 beats per min-1 of predicted maximal value
(220 - age). In the final 30 s of each stage, participants
were asked to report an overall body rating of perceived
exertion (RPE) using a 6-20 numeric scale [21], heart rate
was recorded, and a capillary blood lactate sample was
collected. Subjects were oriented to the RPE scale prior to
initiation of the test.
A fixed marker of 4.0 mmol·L-1  blood was used to
define the onset of blood lactate accumulation (OBLA).
This fixed lactate measurement provides the most rea-
sonable and accurate lactate analysis relative to the scope
of this study and has been shown to be a valid evaluation
of physiological changes with specificity to endurance
performance [17], and improvements in endurance fit-
ness [18].
Immediately following RPE and HR data collection
with 30 s remaining in each stage, subjects while running
were asked to extend their left index finger, which was
prepared with an alcohol pad and dried with gauze. After
preparation, a lancet device was applied to the fingertip
and samples were collected in capillary tubes. All lactate
samples were immediately analyzed in duplicate using an
Accutrend Lactate Analyzer (F. Hoffman-La Roche Ltd,
Basel, Switzerland). After compiling the data, the stage
that elicited 4.0 mmol/L blood lactate which has been
previously identified as the OBLA [22] was used to deter-
mine lactate threshold. OBLA, VO2max@OBLA and
HR@OBLA were all calculated using linear interpolation
b e t w e e n  r e l e v a n t  d a t a  p o i n t s  a s  h a s  b e e n  p r e v i o u s l y
explained by Neville et al. [23].
The treadmill protocol continued until volitional
exhaustion was attained and the highest heart rate expe-
rienced during the test was recorded as Max Heart Rate
(MHR). OBLA was then also identified by the percentage
of maximum heart rate (%MaxHR@OBLA) at which it
occurred.
Supplementation
During the study, subjects were asked to refrain from tak-
ing any other dietary supplements or making changes to
their regular dietary and exercise patterns. The partici-
pants were randomly assigned in a double-blind manner
to receive either β-Alanine or Placebo. The supplements
were provided to the participants in identical, unmarked,
sealed containers, supplied by Athletic Edge Nutrition,
Miami, Florida. Subjects received βA supplement (6.0 g·d-
1 βA, 600 mg N-Acetylcysteine, 2.7 mg alpha-lipoic acid,
45 IU Vitamin E) or a PL (6.0 g·d-1 Rice Flour Maltodex-
trin). Both groups followed the same supplementation
protocol of 3 capsules 3 times daily with meals.
Supplementing with 6.4 g·d-1 of βA for 28 days has been
shown to increase carnosine levels by 60% [4,12] so it can
be assumed that supplemented subjects in this study
experienced a significant increase in intramuscular car-
nosine concentration. Three of the eight subjects in the
βA supplemented group reported tingling in their fingers
and hands. No other side effects were reported by those
individuals supplemented with βA and subjects in the PL
group reported no side effects.
Statistical Analysis
Because of the degree of non-normality in the distribu-
tions, data transformation could not be done to obtain
statistical normality. For this reason, nonparametric sta-
tistical methods were used to analyze the data. The Fried-
man test was used to determine within group differences;
and the Mann-Whitney test was used to determine
between group differences. Data were analyzed using
SPSS for Windows (Version 16.0, 2007 Chicago, IL) Prior
to initiation of the study the alpha level was set at p < 0.05
to determine statistical significance. Data are presented
as means ± standard error (SE).
Results
Participant Characteristics
At baseline there were no differences in age, height, body
mass, BMI, absolute VO2max L.min-1 (4.57 ± 0.8 βA vs.
4.04 ± 0.7 PL) relative VO2max ml.kg.min-1 (58.7 ± 50.0 βA
vs. 50.0 ± 5.2 PL) or max HR beats. min-1(195 ± 10.2 βA
vs. 193.4 ± 14.9 PL) between subjects in the two groups
(Table 1). Table 2 presents the mean and standard error
values for VO2max  (L. min-1), VO2max  (ml.kg-1.min-1),
%VO2max  @ OBLA, VO2@ OBLA (L.min-1) MaxHR
(beats.min-1), HR@OBLA (beats. min-1), and
%HRMax@OBLA for both treatment groups at pre- and
post-testing.
Absolute (L.min-1) and Relative VO2 max (ml.kg-1.min-1)
On day 1 pre-supplementation there were no significant
differences in VO2max between subjects in βA and the PL
groups (p=.154). On day 29 (post-supplementation) sub-
jects in the βA group had significant decreases in both
absolute and relative VO2max values (p = 0.005), while no
changes were observed in the PL group.
%VO2max@OBLA
On day 1 pre-supplementation there were no significant
differences in %VO2max@OBLA between subjects in the
βA and PL groups. On day 29 (post-supplementation)
subjects in the βA group had a significant increase (p =
0.034) in %VO2max@OBLA while no changes were
observed in the PL group.
VO2 @ OBLA
On day 1 pre-supplementation there were no significant
differences in VO2@OBLA (L·min-1) between subjects inJordan et al. Journal of the International Society of Sports Nutrition 2010, 7:20
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the βA and PL groups. On day 29 (post-supplementation)
no changes were observed in the βA group or PL group.
Heart Rate@OBLA and %HRmax@OBLA
On day 1 pre-supplementation there were no significant
differences in heart rate at OBLA (HR@OBLA), or per-
cent maximum heart rate at OBLA (%HRmax@OBLA)
between subjects in the two groups. On day 29 (post-sup-
plementation) subjects in the βA group had a significant
increase (p = 0.005) in HR@OBLA and %HRmax@OBLA
(p = 0.005), while no changes were observed in the PL
group. HR @OBLA increased in 8/8 βA supplemented
subjects versus 7/9 increased for PL and 2/9 (PL)
remained the same post versus pre supplementation. Per-
cent HRmax@OBLA increased in 7/8 (βA) and decreased
in 1/8 βA subjects, whereas 6/9 increased for the PL sub-
jects and 3/9 (PL) decreased post versus pre supplemen-
tation.
Body Mass
There was a statistically significant increase in mean body
mass for the βA group (p = 0.034) post supplementation
while there was no change in the PL group. Mean body
mass for the βA group increased by 0.4 kg (77.9 ± 9.0 to
78.3 ± 9.3 kg) following the 28 day supplementation
period, while no change occurred in the placebo group
(80.6 ± 9.1 to 80.4 ± 9.0 kg).
Body Mass Index (BMI)
There was a change in BMI values pre/post supplementa-
tion (p = 0.034)(βA 23.7 ± 2.3 vs. PL 23.8 ± 2.3) versus
post supplementation (βA 24.9 ± 1.8 vs PL 24.8 ± 1.7).
Rate of Perceived Exertion (RPE)
There were no changes in the final RPE numbers
obtained at test termination in the βA group pre/post
(18.50 ± .42 to 17.50 ± .82) versus the PL group (18.56 ±
.44 to 18.78 ± .32).
Discussion
While previous studies have suggested an ergogenic
effect with βA supplementation in cyclists, this was the
first study using running as the exercise protocol. In the
current study, results showed that βA supplementation
delayed OBLA as illustrated by significant increases in
HR@OBLA, %HRmax @ OBLA compared to the PL
group. These findings are in part consistent with Zoeller
et al. who noted an improvement in power output at lac-
tate threshold on a cycle ergometer [5]. These researchers
observed no change in ventilatory measures (VO2peak at
OBLA), however , it should be noted that Zoeller et al.
used a much lower dose of βA (3.2 g·d-1) versus the 6.0
g·d-1 used in this study [5].
While muscle levels of carnosine were not measured
for this study previous research has indicated that 4-10
weeks of βA supplementation (2.4-6.4 g·d-1) increased
muscle carnosine levels 37-80% [4,7,8,12] and that a sig-
nificant relationship exists between carnosine concentra-
tion and high intensity exercise performance [19].
Furthermore, carnosine levels are higher in trained ath-
letes [20,24,25] and body builders [26] and have been
shown to increase in response to high intensity exercise
such as sprint training [27].
Ergogenic Mechanism of Carnosine
Physically active individuals have higher muscle carnos-
ine concentrations than their sedentary counterparts
[20,25-28] and it is clear that both supplementation with
βA [4,7,8,12] and high intensity exercise [28] indepen-
dently increase muscle carnosine levels. While the exact
mechanism of action concerning carnosine and exercise
Table 2: Exercise Parameters Pre and Post Supplementation.
Day 1 Day 29
βA PL βA PL
VO2max (L·min-1) 4.57 ± 0.8 4.04 ± 0.7 4.31 ± 0.8** 4.18 ± 0.8
VO2max (ml·kg·min-1) 58.7 ± 6.1 50.0 ± 5.2 55.0 ± 6.2** 51.7 ± 5.1
VO2@OBLA (L·min-1) 3.16 ± 0.7 2.97 ± 0.6 3.25 ± 0.7 3.11 ± 0.7
%VO2max@OBLA (%) 69.1 ± 11.0 73.3 ± 7.3 75.6 ± 10.7* 74.3 ± 7.3
Max HR (beats·min-1) 195.0 ± 10.2 193.4 ± 14.9 196.5 ± 13.1 193.1 ± 9.4
HR @OBLA(beats·min-1) 161.6 ± 19.2 166.8 ± 15.8 173.6 ± 9.9* 169.6 ± 16.1
%HRmax @OBLA (%) 83.0 ± 9.7 86.3 ± 4.8 88.6 ± 3.7* 87.9 ± 7.2
Values are means ± SE; *p < 0.05 Pre Supplementation βA vs. Post Supplementation βA **p < 0.01 Pre Supplementation βA vs. Post 
Supplementation βAJordan et al. Journal of the International Society of Sports Nutrition 2010, 7:20
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performance remains unclear, suggested roles of carnos-
ine include acting as an intramuscular antioxidant [29],
regulation of calcium sensitivity and excitation-contrac-
tion (E-C) coupling [30,31], protection against glycation
by acting as a sacrificial peptide [32], and prevention of
protein-protein cross links by reacting with protein-car-
bonyl groups [33]. The most relevant mechanism of
action to this study would be the role of carnosine as an
intramuscular buffer against pH decline during exercise.
Effect of BA Supplementation on Lactate Kinetics
Lactate kinetics following βA supplementation has been
evaluated in three previous studies. While lactate is not
the cause of the [H+] accumulation, the metabolic envi-
ronment that causes pH decline also increases lactate
production, making lactate a good marker for the condi-
tions that induce metabolic acidosis [15]. As suggested by
Van Thienen et al., enhanced buffering capacity should
allow for enhanced glycolytic energy production and
result in an overall increase in lactate production [9].
However, these researchers did not see a significant
change in blood lactate concentration following a 30 s
cycle sprint at the conclusion of a 110 minute time trial.
Derave et al. also failed to show a difference in lactate
concentrations 90 and 180 s after a 400 m run for A group
as compared with PL group [7]. Conversely, in evaluating
lactate concentration during incremental increases in
cycling intensity, Zoeller et al. noted an increase in power
output (W) at Lactate Threshold [5]. However, the abso-
lute VO2peak was unchanged at LT.
Body Mass
Body mass was increased in the βA group while there was
no change in the PL group. This contradicts previous
studies reporting no change in body mass in response to
βA supplementation [4,8]. Smith et al noted no change in
body mass, but did see a significant increase in lean body
mass during the first 3 weeks of supplementation (6 g·d-1
βA) in combination with high intensity interval training
[10]. Zoeller et al. reported that supplementation with
either βA or Creatine alone did not elicit increases in
body mass, but in the group receiving both supplements,
body mass was increased [5]. Hoffman et al. noted that
when subjects were supplemented with either placebo,
creatine, βA, or creatine + βA, the creatine + βA group
increased lean body mass to the greatest extent [6]. Previ-
ous authors have noted that the proposed effects of βA
supplementation and an increase lean body mass or body
mass is due to a decrease in acidosis along with subse-
quent increases in training volume [6,10].
Implications of Study Results
The present study is the first to our knowledge to exam-
ine the effects of βA on OBLA during incremental stages
of running. After 28 days of 6.0 g·d-1 of βA supplementa-
tion, the βA group had a delay in OBLA as determined by
increases in HR@OBLA and %MaxHR@OBLA. The find-
ings of this study are consistent with previously discussed
studies showing a delay in fatigue after βA supplementa-
tion [1-5,7,9,10]. A delay or rightward shift in OBLA dur-
ing a high intensity exercise offers a significant advantage
to an athlete trying to maintain repeated or prolonged
high intensity muscle contractions. In addition to the HR
findings, there was also an observed increase in
%VO2max@OBLA within the βA group. However, the
authors feel this may be misleading as there was also a
decrease in the VO2max  values post supplementation
within the βA group. Therefore, the increase in
%VO2max@OBLA may simply be due to a decrease in the
VO2max  v a l u e .  T h i s  d e c r e a s e  i n  V O 2max  was an unex-
pected finding as it is indicative of a reduced aerobic
capacity and is not a typical training response.
Limitations
The supplement used in this study contained additional
antioxidants (600 mg N-Acetylcysteine, 2.7 mg alpha-
lipoic acid, and 45 IU Vitamin E) which, per manufac-
turer claims, may work synergistically with the role of
carnosine as an intramuscular antioxidant. However pre-
vious research on antioxidants and exercise suggest that
an applicable performance enhancement due to antioxi-
dant activity is unlikely [34-40]. Furthermore, the previ-
ously suggested ergogenic mechanism of carnosine lies
not in its antioxidant function, but in its involvement as
an intramuscular buffer [19].
Subjects were asked to not change their regular dietary
or exercise habits during the 28 days of the study, refrain
from taking any other dietary supplements, avoid caffeine
or vigorous exercise for at least 24 hrs prior to exercise
testing, and consume 3 pills 3 times daily at meals. Verifi-
cation of these controls were limited to verbal confirma-
tions by the subjects. Therefore, it may be possible that
individuals receiving the βA supplementation were exer-
cising at a greater intensity and this allowed for the signif-
icant increase in body mass. Furthermore, although a
Tanita scale was used to weigh subjects, body composi-
tion data was not collected. Hence, the increase in body
mass noted in this study cannot be further differentiated
into lean body mass or fat mass.
Conclusions
The results of this study suggest 28 days of βA supple-
mentation may enhance submaximal endurance perfor-
mance as measured by OBLA. The authors suggest that
βA supplementation may have optimized the relative
contribution of the anaerobic energy system but may
have also reduced the capacity of the aerobic energy sys-Jordan et al. Journal of the International Society of Sports Nutrition 2010, 7:20
http://www.jissn.com/content/7/1/20
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tem. More specifically, OBLA was delayed based on
higher HR@OBLA and %HRmax@OBLA in the group of
individuals receiving the βA versus the PL. Future
research is needed to confirm these results and to test for
performance related outcomes specific to distance run-
ning.
Future Research
Future studies should focus on looking at the effects of
βA on 10-20 km simulated endurance road race perfor-
mance. With this, a close examination of VO2max should
be considered. It would also be of interest to determine
the ergogenic effects of βA on intermittent sports, such as
soccer, hockey, basketball or football, which require a
combination of endurance and sprint performance.
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